{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"10","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Progression free survival is defined as time in weeks from start of study treatment to first documentation of objective tumor progression or up to death due to any cause, whichever occurs first.","dispersionType":"Full Range","groups":[{"description":"Patients receive Akt/ERK inhibitor ONC201 625 mg PO every 7 days. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"ONC201 625 mg"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"every 3 months for 1 year, then every 6 months, up to 6 years","title":"Progression-free Survival (PFS)- (Phase 2)","type":"SECONDARY","unitOfMeasure":"weeks"}